Efficacy and safety in SGLT2 inhibitor for non-diabetes complicated by non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.
- Conditions
- non-diabetes complicated by non-alcoholic fatty liver disease / non-alcoholic steatohepatitis
- Registration Number
- JPRN-UMIN000031041
- Lead Sponsor
- Kobe university school of medicine, Diabetes and Endocrinoplogy
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Not provided
(1)Choronic hepatitis such as liver cirrhosis, viral hepatitis, alcoholic hepatitis (2)Known or suspected abuse of alcohol (3)Treatment with steroid (4)Patients with severe vascular disease such as stroke, myocardial infarction within the past 6 months (5)Impaired liver function, defined as alanine aminotransferase >4 times upper limit of normal, or Child-pugh C cirrhosis (6)Impaired renal function defined as eGFR <45ml/min (7)Treatment with SGLT2 inhibitor or pioglitazone (8)Pregnancy or breast feeding (9)Cancer and other severe disease (10)Patients with mental illness or drug addicts (11)Patients who are difficult to perform MRI examination such as implantable defibrillators and internal metals (12)Others judged unsuitable by researchers
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method